default author photo

Nuradh Joseph

District General Hospital Matara

Sri Lanka Cancer Research Group

SCHOLARLY PAPERS

3

DOWNLOADS

169

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

A Hypoxia Biomarker Does Not Predict Benefit from Giving Chemotherapy with Radiotherapy in the BC2001 Randomised Controlled Trial

Number of pages: 35 Posted: 22 Jun 2023
The University of Manchester - Translational Radiobiology Group, The University of Manchester - Translational Radiobiology Group, District General Hospital Matara, The University of Manchester - Translational Radiobiology Group, The University of Manchester - Translational Radiobiology Group, The University of Manchester - Translational Radiobiology Group, The University of Manchester - Translational Radiobiology Group, The University of Manchester - Translational Radiobiology Group, The University of Manchester - Translational Radiobiology Group, The University of Manchester - Translational Radiobiology Group, The University of Manchester - Translational Radiobiology Group, University of Sheffield - Department of Oncology & Metabolism, Royal Shrewsbury Hospital - Pathology Centre, Institute of Cancer Research (ICR) - Clinical Trials and Statistics Unit (ICR-CTSU), Institute of Cancer Research (ICR) - Clinical Trials and Statistics Unit (ICR-CTSU), Royal Marsden NHS Foundation Trust - Department of Oncology, Royal Marsden NHS Foundation Trust - Department of Oncology and The University of Manchester - Translational Radiobiology Group
Downloads 66 (907,769)

Abstract:

Loading...

Hypoxia, radiotherapy, hypofractionation, BCON, BC2001, chemotherapy, transcriptomics

2.

Cost-Effectiveness of Novel Targeted Adjuvant Therapies in Early Breast Cancer in Sri Lanka: A Health System Perspective

Number of pages: 21 Posted: 24 Sep 2025
Nuradh Joseph and Sameera Senanayake
District General Hospital Matara and Duke-NUS Medical School
Downloads 52 (1,063,489)

Abstract:

Loading...

Sri Lanka, breast cancer, cost-effectiveness analysis, adjuvant therapy, health technology assessment, LMIC

3.

The Cost-Effectiveness of Neoadjuvant and Adjuvant Novel Cancer Therapies in Stage II-III Non-Small Cell Lung Cancer: Insights for Low and Middle-Income Countries from Sri Lanka

Number of pages: 23 Posted: 11 Nov 2025
District General Hospital Matara, National University of Singapore (NUS) - Duke-NUS Medical School and National University of Singapore (NUS) - Duke-NUS Medical School
Downloads 51 (1,052,702)

Abstract:

Loading...

lung cancer, adjuvant treatment, neoadjuvant treatment, novel cancer therapeutics, immunotherapy, health economics, cost-effectiveness analysis, low and middle income countries, Markov modelling